AstraZeneca Caps Patient Out-of-Pocket Costs at $35 Per Month for Its US Inhaled Respiratory Portfolio
March 19, 2024
March 19, 2024
WILMINGTON, Delaware, March 19 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on March 18, 2024:
AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary dise . . .
AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary dise . . .